arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development Collaboration With Shire

arGEN-X Reaches Milestone in Simple Antibody™ Research and Product Development
                           Collaboration With Shire

  PR Newswire

  BREDA, the Netherlands and GHENT, Belgium, September 19, 2013

BREDA, the Netherlands and GHENT, Belgium, September 19, 2013 /PRNewswire/ --

arGEN-X, a clinical stage human monoclonal antibody therapeutics company,
announces it has attained a key success milestone in its SIMPLE Antibody™
research and product development collaboration with the Human Genetic
Therapies division of Shire Pharmaceuticals. The milestone, which triggered an
undisclosed payment from Shire, was the first demonstration of in vivo proof
of concept for one of the antibody discovery programs undertaken in the

Under their February 29, 2012 agreement, the companies are collaborating to
create human therapeutic antibodies against complex targets involved in
severe, rare genetic diseases. Shire has an option to license the most
promising antibody leads from each collaborative program for further
development and commercialization worldwide, in return for milestone and
royalty payments. Under the terms of the license, arGEN-X has already received
technology access fees and research funding and is eligible to receive
preclinical success payments.

"We are pleased with the excellent progress that has resulted from an
outstanding joint effort between our teams," said Hans de Haard, PhD, Chief
Scientific Officer of arGEN-X. "This collaboration milestone is testament to
the superiority of our proprietary SIMPLE Antibody™ platform and reinforces
our brand in the complex targets space."

About arGEN-X  -

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly
developing a product pipeline using its unique suite of antibody technologies.
arGEN-X is creating first and best in class antibody therapeutics with highly
differentiated target product profiles. Its therapeutic antibody programs,
focused on cancer and autoimmune indications, are designed to deliver tangible
benefits to patients with these diseases.

arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of
high quality human antibodies, enabling optimal product choice. SIMPLE
Antibodies™ are able to address and modulate any disease target, including
complex receptors and highly conserved targets often intractable with other
antibody technologies. SIMPLE Antibody™ generated leads are further
differentiated as products through enhancement of cell killing properties
(POTELLIGENT ^® , licensed from BioWa Inc.) and optimization of circulation
time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™
technology, to potentiate the clearance of disease-causing autoantibodies.

In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its
most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of
action in hematological and virally-induced solid tumors. A Phase Ib trial for
ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, was
initiated in September 2013.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an
independent, unencumbered patent position and is free of target gatekeeping

SIMPLE stands for S uperior I mmunodiversity with M inimal P rotein L ead E

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For further information, please contact: Citigate Dewe Rogerson David
DibleMark Swallow T: +44-207-282-2949/2948 E: E: arGEN-X Tim Van Hauwermeiren, MSc, eMBA Chief
Executive Officer T: +31-6-122-85-257 E: Debbie Allen,
Ph.D. Senior Director, Business Development T: +44-7974-979479 E:
Press spacebar to pause and continue. Press esc to stop.